Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAlumasc Group Regulatory News (ALU)

Share Price Information for Alumasc Group (ALU)

Share Price is delayed by 15 minutes
Get Live Data
240.00    5.00 (2.13%)
Bid:
235.00
Ask:
245.00
Spread: 10.00 (4.255%)
Market Cap: £86.30m
ALU Live PriceLast checked at - London Stock Exchange

Intraday Alumasc Group Share Chart

Trading Statement

19 Jan 2021 07:00

RNS Number : 0821M
Alumasc Group PLC
19 January 2021
 

19 January 2021

THE ALUMASC GROUP PLC

("ALUMASC")

TRADING UPDATE FOR SIX MONTHS ENDED 31 DECEMBER 2020

 

Alumasc, the premium building products, systems, and solutions Group, today provides a trading update for the six months ended 31 December 2020, ahead of publication of its half-year results on Thursday 4 February 2021.

Our absolute focus continues to be the safety of our employees, customers, suppliers, and sub-contractors as we continue to manage with the Covid-19 pandemic and the latest lockdown guidelines.

Record Half Year Performance

Further to our AGM Trading Update on 22 October 2020, which reported a strong performance in the first quarter, we are very pleased to report that conditions in our markets have remained positive and that the Group's trading performance has continued through to the end of the first half of the financial year, with a record profit for the period being achieved. On an unaudited basis, for the first six months of the year:

· Revenue increased 11% versus the prior year to £45.6m

· Underlying PBT increased significantly, from £2.3m to £6.0m

· Cash generation has also been strong in the first half, with net bank debt reducing from £4.3m at 30 June 2020 to £0.2m at 31 December 2020.

 

Pleasingly, all our divisions have contributed to the strong performance. While trading in the period includes an element of catch-up demand following the UK's first national lockdown and has benefitted from a range of Government support for the construction industry, our businesses have also been successful in winning market share and have been further supported by encouraging export sales. Additionally, the restructuring during FY2020, which provided £2.4 million in annual cost savings, benefitted margins. Levolux also continues to respond well to the business's turnaround plan, achieving a profit in each month of the first half of this financial year.

Outlook

The business has entered H2 with good momentum, a healthy forward sales position, and a well-capitalised balance sheet, creating the potential to deliver a strong result for the year. Nevertheless, we remain mindful of the continued economic uncertainties, particularly the risk of disruption to our business and markets in the near term as a result of the on-going pandemic and the establishment of efficient cross-border goods movement following the entry into the Free Trade Agreement with the EU. Conditions in our markets, particularly in the new build housing and RMI sectors, have been very supportive coming into the second half and we would anticipate demand remaining good through the coming months. We are also continuing to monitor the potential impact of changes to UK Government incentives within the housebuilding industry, notably around the current Help to Buy Scheme being extended beyond 28 February 2021 and Stamp Duty and changes here may affect our final quarter, albeit the potential impact is difficult to predict. However, we are encouraged by the UK's accelerating rollout of vaccines and mass testing, which should provide some counterbalance in our markets. Overall, this has been a most encouraging performance by Alumasc in the first half and there is an excellent platform to deliver sustainable shareholder value.

Paul Hooper, CEO, commented, "It is very encouraging to see Alumasc's achievement of a double digit growth in revenues and also a double digit return on sales and H1 has absolutely shown the great potential for the Group. In light of the businesses' momentum and strong cash conversion, a resumption of Alumasc's previous dividend policy is being considered by the Board."

This announcement contains inside information.

Enquiries:

Paul Hooper, CEO

Helen Ashton, Group Company Secretary

+ 44 (0) 1536 383844

+ 44 (0) 1536 383812

 

Peel Hunt (Broker)

Mike Bell + 44 (0)207 418 8831

 

finnCap (NOMAD)

Julian Blunt + 44 (0)207 220 0561

Camarco:

Ginny Pulbrook + 44 (0)203 757 4992

Tom Huddart + 44 (0)203 757 4991

Email: alumasc@camarco.co.uk

 

 

Notes to Editors:

Alumasc is a UK-based supplier of premium building products, systems and solutions. Almost 80% of group sales are driven by building regulations and specifications (architects and structural engineers) because of the performance characteristics offered.

 

The Group has three business segments with strong positions and brands in their individual markets. The three segments are: Water Management; Building Envelope; and Housebuilding Products.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFLFSRLFITLIL
Date   Source Headline
13th May 20217:00 amRNSTrading Update
13th Apr 20212:13 pmRNSDirector/PDMR Shareholding
9th Apr 20213:16 pmRNSDirector/PDMR Shareholding
19th Feb 20211:30 pmRNSDirector/PDMR Shareholding
5th Feb 202112:20 pmRNSDirector/PDMR Shareholding
4th Feb 20217:01 amRNSAppointment of Group Finance Director
4th Feb 20217:00 amRNSInterim results
19th Jan 20219:05 amRNSSecond Price Monitoring Extn
19th Jan 20219:00 amRNSPrice Monitoring Extension
19th Jan 20217:00 amRNSTrading Statement
18th Nov 20203:20 pmRNSDirectorate Change
23rd Oct 20204:35 pmRNSPrice Monitoring Extension
22nd Oct 20203:30 pmRNSResult of AGM
22nd Oct 20207:00 amRNSAGM Trading Update
15th Oct 20201:01 pmRNSDirector/PDMR Shareholding
21st Sep 20201:30 pmRNSNotice of AGM
8th Sep 20207:00 amRNSFull Year Results
19th Aug 202011:49 amRNSNotice of Results
7th Aug 20202:30 pmRNSDirector/PDMR Shareholding
3rd Aug 202011:32 amRNSHolding(s) in Company
29th Jul 202011:52 amRNSDirector/PDMR Shareholding
27th Jul 20202:51 pmRNSDirector/PDMR Shareholding
27th Jul 202012:13 pmRNSDirector/PDMR Shareholding
27th Jul 20208:51 amRNSDirector/PDMR Shareholding
27th Jul 20208:51 amRNSDirector/PDMR Shareholding
23rd Jul 20207:00 amRNSTrading Statement
9th Jun 20201:30 pmRNSHolding(s) in Company
19th May 20207:00 amRNSContract wins
11th May 20202:30 pmRNSDirector/PDMR Shareholding
29th Apr 20202:14 pmRNSHolding(s) in Company
27th Apr 20207:00 amRNSCOVID-19 Further Update
23rd Apr 202011:48 amRNSResults of General Meeting
16th Apr 20203:27 pmRNSDirector/PDMR Shareholding
7th Apr 20202:31 pmRNSDirector/PDMR Shareholding
1st Apr 20203:48 pmRNSCOVID-19 Update
31st Mar 202011:00 amRNSNotice of GM
27th Mar 20207:00 amRNSCOVID-19 Update
20th Mar 20202:39 pmRNSDirector/PDMR Shareholding
19th Mar 20203:00 pmRNSDirector/PDMR Shareholding
12th Mar 20202:30 pmRNSHolding(s) in Company
2nd Mar 202010:24 amRNSHolding(s) in Company
26th Feb 202012:38 pmRNSHolding(s) in Company
4th Feb 20207:00 amRNSInterim Results
8th Jan 202011:20 amRNSNotice of Results
1st Nov 20192:26 pmRNSHolding(s) in Company
1st Nov 20192:22 pmRNSHolding(s) in Company
24th Oct 20193:30 pmRNSResult of AGM
24th Oct 20197:00 amRNSAGM Statement
17th Oct 201910:30 amRNSDirector/PDMR Shareholding
2nd Oct 20193:00 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.